UC Davis Health System researchers who are working to speed therapies to patients suffering from critical limb ischemia, osteoporosis and Huntington’s disease received approval today for three separate research grants from the state’s stem cell agency totaling more than $53 million. Each of the research studies that can now begin at UC Davis are specifically designed to lead to U.S. Food and Drug Administration approval of human clinical trials using stem cells and regenerative therapies.
At today’s meeting of the California Institute for Regenerative Medicine (CIRM) in San Francisco, the agency’s 29-member governing board approved five other grant
Researchers have reversed aging in old mice by injecting them with a longevity gene and rejuvenating their stem cells‘ regenerative potential.
The study by University of California-Berkeley biologists represents a major advance in understanding the molecular mechanisms behind aging, paving the way for the development of targeted treatments for age-related degenerative diseases.
The found that SIRT3, one among a class of proteins known as sirtuins, plays an important role in helping aged blood stem cells cope with stress, the journal Cell reports.
When they infused the blood stem cells of old mice with SIRT3, the treatment boosted the formation of new blood
A team led by Peter Schultz, Scripps Family Chair Professor and member of the Skaggs Institute for Chemical Biology at The Scripps Research Institute, has been awarded a $4.3 million grant from the California Institute for Regenerative Medicine (CIRM) to research stem-cell-based therapies to treat multiple sclerosis.
Because stem cells can change or differentiate into many different cell types (such as nerve cells, muscle cells, and skin cells), they hold the life-changing medical potential to provide a source of cells to replace those permanently lost by a patient.
The Scripps Research project focuses on restoring the myelin sheath—a protective covering that
International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.
These products represent milestone
Image via CrunchBase
Two critical programs funded by the California Institute for Regenerative Medicine, the state stem cell agency, got a $11 million increase today when the agency’s 29-member Governing Board voted to approve funding for two additional grants in the Training II program and five additional grants in the Bridges program.
The grants voted in today had been recommended by the Scientific and Medical Research Funding Working Group for funding if funds permit. In January 2009, when the Board considered those applications, they voted to fund only the top tier due to uncertainty in the bond market. With improvements in